论文部分内容阅读
目的研究晚期胃癌患者接受奥沙利铂联合卡培他滨化疗疗效和安全性。方法选取2012年2月—2016年5月接受奥沙利铂联合卡培他滨化疗治疗的晚期胃癌患者98例为研究对象。所有患者均给予130 mg/m~2奥沙利铂+500 ml,5%的葡萄糖注射液静脉滴注2～3h,化疗当天口服1 200 mg/m~2卡培他滨,2次/d,早、晚服用,采取3周给药方案:连用2周,第3周停用,连续治疗3个周期后评价临床疗效与不良反应发生情况。结果 98例晚期胃癌患者中完全缓解(CR)6例(6.12%),部分缓解(PR)34例(34.69%),肿瘤稳定(SD)37例(37.76%),肿瘤进展(PR)21例(21.43%),治疗总有效率为40.82%,肿瘤控制率为78.57%;不良反应主要为手足综合征、外周神经炎、腹泻、口腔炎等,均可耐受。结论奥沙利铂联合卡培他滨化疗治疗晚期胃癌患者有效率较高,不良反应较轻可耐受,值得临床上应用。
Objective To investigate the efficacy and safety of oxaliplatin combined with capecitabine in patients with advanced gastric cancer. Methods From January 2012 to May 2016, 98 patients with advanced gastric cancer who received oxaliplatin combined with capecitabine chemotherapy were selected as study subjects. All patients were given 130 mg/m 2 oxaliplatin + 500 ml, 5% glucose injection intravenously for 2-3 hours, orally 1,200 mg/m 2 capecitabine on the same day of chemotherapy, twice a day. , Taking morning and evening, take 3 weeks dosing regimen: continuous use for 2 weeks, disable at 3 weeks, evaluate clinical efficacy and adverse reactions after 3 consecutive cycles. Results Of 98 patients with advanced gastric cancer, 6 were complete remission (CR) (6.12%), 34 were partial remission (PR) (34.69%), 37 were stable (SD) (37.76%), and 21 were tumor progression (PR). (21.43%), the total effective rate was 40.82%, and the tumor control rate was 78.57%. The adverse reactions were mainly hand-foot syndrome, peripheral neuritis, diarrhea, and stomatitis, which were all tolerable. Conclusion Oxaliplatin combined with capecitabine chemotherapy is effective in the treatment of advanced gastric cancer patients. The adverse reactions are mild and tolerable. It is worthy of clinical application.